Lupin receives tentative approval from USFDA for Valbenazine capsules
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide
Obeticholic Acid Tablets (RLD Ocaliva) had estimated annual sales of US $255 million in the US (IQVIA MAT December 2022).
Essex enriches and complements Emmes’ services
Integration of modern and traditional medicine to facilitate the illness to wellness journey
This initiative encapsulates the essence of OPPI’s commitment towards enabling a healthier India
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
Subscribe To Our Newsletter & Stay Updated